NASDAQ · ALECHealthcareBiotechnology

Alector financials

$1.87−2.60%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
Revenue$21.0M$100.6M$97.1M$133.6M$207.1M$21.1M$21.2M
Gross profit$21.0M$100.6M$97.1M$133.6M$207.1M$21.1M$21.2M
Gross margin100.0%100.0%100.0%100.0%100.0%100.0%100.0%
Operating income-$156.0M-$145.0M-$151.7M-$137.8M-$37.4M-$195.2M-$114.4M
Net income-$142.9M-$119.0M-$130.4M-$133.3M-$36.3M-$190.2M-$105.4M
Net margin−679.2%−118.4%−134.3%−99.8%−17.5%−901.6%−496.7%
Diluted EPS$-1.39$-1.23$-1.56$-1.62$-0.45$-2.45$-1.71
EBITDA-$150.3M-$139.6M-$146.0M-$132.1M-$31.0M-$189.3M-$110.6M
Operating cash flow-$184.0M-$229.9M-$184.2M-$20.3M$298.6M-$166.7M-$99.3M
Free cash flow-$184.1M-$231.2M-$186.5M-$24.4M$295.3M-$171.8M-$114.6M
Diluted shares103.0M96.6M83.7M82.5M80.4M77.8M61.7M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$65.8M$33.0M$74.6M$154.3M$329.2M$50.0M
Short-term investments$190.2M$380.4M$474.3M$558.5M$406.1M$363.3M
Total debt$9.7M$9.4M$0.00$0.00$0.00$0.00
Total assets$293.2M$468.3M$621.8M$787.6M$814.7M$488.3M
Total liabilities$262.6M$341.5M$487.7M$573.2M$513.9M$220.7M
Shareholders' equity$30.6M$126.8M$134.2M$214.4M$300.7M$267.5M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology